
|Articles|February 1, 2004
Acne treatment comes of age
Waikoloa, Hawaii - The large, multicenter B.E.S.T. (Balancing Efficacy, Speed and Tolerability) clinical trial provides real-world data, reinforcing the conclusion that tazarotene 0.1 percent cream (Tazorac for acne) applied once daily in the evening is a highly and rapidly effective, well-tolerated treatment for acne vulgaris, said Dina N. Anderson, M.D., at the annual Hawaii Dermatology Seminar in January.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
3
Introducing Dermatology Times NP/PA Connect
4
Narrow-Spectrum Sarecycline Approved for Moderate to Severe Acne in China
5











